Abivax SA

ABVX

About

Abivax SA
Abivax SA
ABVX.US

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Profile

Company Name
ABIVAX Société Anonyme
Market
NasdaqGM
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management